Koutif Therapeutics

Executive Summary

Koutif Therapeutics is a preclinical-stage biotechnology company developing novel small molecule therapies that target Fbxo3 E3 ligase to modulate the ubiquitin degradation pathway, with applications in oncology and inflammatory diseases. Founded in 2021 and headquartered in Cambridge, MA, the company exclusively licenses foundational intellectual property from the University of Pittsburgh and the U.S. Department of Veterans Affairs. Koutif's approach aims to inhibit specific RNA-modifying proteins to regulate inflammatory cascades, offering a potentially differentiated mechanism of action. The company is currently in the early research and development phase, with no disclosed pipeline or financial backing. Given its early stage, Koutif's near-term focus is expected to be on lead optimization, IND-enabling studies, and securing Series A financing to advance its lead program toward clinical development.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination60% success
• Q1 2027IND-enabling studies initiation40% success
• Q4 2026Series A funding announcement50% success